These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 8115891)
1. Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. Paterson RW; Paat JJ; Steele GH; Hathaway SC; Wong JG South Med J; 1994 Feb; 87(2):236-42. PubMed ID: 8115891 [TBL] [Abstract][Full Text] [Related]
2. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695 [TBL] [Abstract][Full Text] [Related]
3. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615 [TBL] [Abstract][Full Text] [Related]
4. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Zambon A; Hokanson JE; Brown BG; Brunzell JD Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998 [TBL] [Abstract][Full Text] [Related]
5. Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. Zambon A; Brown BG; Hokanson JE; Motulsky AG; Brunzell JD J Intern Med; 2006 Apr; 259(4):401-9. PubMed ID: 16594908 [TBL] [Abstract][Full Text] [Related]
13. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. Frisinghelli A; Mafrici A Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568 [TBL] [Abstract][Full Text] [Related]
14. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687 [TBL] [Abstract][Full Text] [Related]
15. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143 [TBL] [Abstract][Full Text] [Related]
16. Analysis of angiographic trial data in women. Havel RJ Drugs; 1994; 47 Suppl 2():11-5. PubMed ID: 7517829 [TBL] [Abstract][Full Text] [Related]
17. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754 [TBL] [Abstract][Full Text] [Related]
18. Effect of lipid-lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Nash DT; Gensini G; Esente P Int J Cardiol; 1982; 2(1):43-55. PubMed ID: 7129689 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Hunninghake DB Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501 [TBL] [Abstract][Full Text] [Related]